BLEPHAMIDE S.O.P.
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BLEPHAMIDE S.O.P. (BLEPHAMIDE S.O.P.).
Combination of sulfonamide (sulfacetamide) and corticosteroid (prednisolone). Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis; prednisolone suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin synthesis.
| Metabolism | Sulfacetamide undergoes hepatic acetylation and renal excretion; prednisolone is metabolized hepatically via CYP3A4 to inactive metabolites. |
| Excretion | Renal (70% sulfacetamide; prednisolone undergoes hepatic metabolism with <1% excreted unchanged in urine), biliary/fecal (minor for both components). |
| Half-life | Sulfacetamide: 7-13 hours (prolonged in renal impairment). Prednisolone: 2.1-3.5 hours (terminal half-life; clinical effects persist longer due to receptor-mediated action). |
| Protein binding | Sulfacetamide: 70-85% bound to albumin. Prednisolone: 90-95% bound to albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Sulfacetamide: 0.3 L/kg (distributes into total body water; penetrates ocular tissues). Prednisolone: 0.6 L/kg (extensively distributed; high tissue penetration). |
| Bioavailability | Ocular: not applicable (topical); systemic absorption negligible (<10% for both components after conjunctival application). |
| Onset of Action | Ocular: within 1-2 hours for anti-inflammatory effect (prednisolone); antibacterial effect (sulfacetamide) begins within 1 hour. |
| Duration of Action | Ocular: 6-8 hours (maintained by sustained-release formulation; less frequent dosing than solution). |
| Molecular Weight | Sulfacetamide: 214.24 Da; Prednisolone: 360.44 Da |
Instill 1 drop into the affected eye(s) every 4 to 6 hours and at bedtime, or as directed. For severe cases, may be initiated with 1 drop every 1 to 2 hours until response improves, then taper.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for topical ophthalmic use. Systemic absorption is minimal; however, in severe renal impairment (GFR <15 mL/min), consider potential for sulfonamide accumulation but no specific dose modification is recommended. |
| Liver impairment | No dose adjustment recommended for topical ophthalmic use. In severe hepatic impairment (Child-Pugh C), use with caution due to potential sulfonamide toxicity, but no specific dose modification is established. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Use only if potential benefit justifies risk. Dosing per adult guidelines if used: 1 drop into affected eye(s) every 4–6 hours, adjusted based on response. |
| Geriatric use | No specific dose adjustment required. Use same dosing as adults, but monitor for increased intraocular pressure or corticosteroid-related adverse effects due to possible age-related ocular conditions. Consider lower initial frequency if comorbid conditions. |
| 1st trimester | Avoid; sulfonamides may cause kernicterus; corticosteroids may increase risk of cleft palate. |
| 2nd trimester | Use only if clearly needed; potential for adrenal suppression in fetus. |
| 3rd trimester | Avoid; risk of kernicterus in newborn from sulfacetamide; possible adrenal suppression from prednisolone. |
Clinical note
Comprehensive clinical and safety monograph for BLEPHAMIDE S.O.P. (BLEPHAMIDE S.O.P.).
| Placental transfer | Both sulfacetamide and prednisolone cross the placenta. Sulfacetamide crosses readily; prednisolone is partially inactivated but may reach fetus. |
| Breastfeeding | Minimal systemic absorption; theoretical risk of sulfonamide displacement of bilirubin in infants with G6PD deficiency or hyperbilirubinemia. Consider benefit vs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to sulfonamides or corticosteroidsViral, fungal, or mycobacterial eye infectionsEpithelial herpes simplex keratitis (dendritic keratitis)
| Precautions | Prolonged use may increase intraocular pressure (IOP), glaucoma risk, cataract formation, and secondary infections, May mask or worsen fungal/viral infections, Use with caution in glaucoma patients, Monitor IOP with prolonged use, Hypersensitivity to sulfonamides or corticosteroids, Avoid use in patients with epithelial herpes simplex keratitis or vaccinia/varicella |
| Food/Dietary | None known. No specific dietary restrictions required. However, if systemic absorption occurs (e.g., with prolonged use), concurrent ingestion of large amounts of potassium-depleting foods (e.g., licorice) may theoretically affect corticosteroid-related electrolyte balance, but this is not clinically significant with standard ophthalmic dosing. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Category C. Sulfonamides and corticosteroids are associated with teratogenic risks, including cleft palate (corticosteroids) and kernicterus (sulfonamides near term). First trimester: potential for neural tube defects, cardiac anomalies, and oral clefts from corticosteroid component. Second/third trimester: sulfonamide may cause hyperbilirubinemia and kernicterus in neonates; corticosteroids may increase risk of intrauterine growth restriction, adrenal suppression, and preterm birth. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose (corticosteroid-induced hyperglycemia), and intraocular pressure. Fetal surveillance: ultrasound for growth restriction in prolonged use during second/third trimester. Neonatal monitoring for jaundice, bilirubin levels, and signs of kernicterus if used near term. Also observe for neonatal adrenal suppression if maternal corticosteroids were used in high doses or for prolonged periods. |
| Fertility Effects | No known direct effects on fertility from ophthalmic sulfacetamide/prednisolone. However, systemic absorption may be minimal. High-dose or prolonged systemic corticosteroids can cause menstrual irregularities and reduced spermatogenesis, but this is unlikely with ophthalmic use. No specific human data on fertility effects. |
| Clinical Pearls | BLEPHAMIDE S.O.P. is a fixed combination of sulfacetamide (antibacterial) and prednisolone acetate (corticosteroid). Use only when bacterial infection coexists with steroid-responsive inflammatory ocular conditions. Shake well before use; the sterile ophthalmic suspension contains both active ingredients. Do not use for viral, fungal, or mycobacterial ocular infections. Prolonged use may increase intraocular pressure (IOP) in susceptible patients; monitor IOP regularly. Discontinue if sensitivity or superinfection occurs. |
| Patient Advice | Shake the bottle well before each use to ensure the medication is evenly mixed. · Wash hands before applying. Tilt head back, pull down lower eyelid to create a pouch, and instill the prescribed number of drops. Avoid touching the dropper tip to any surface to prevent contamination. · Do not wear contact lenses during treatment. If prescribed, wait at least 15 minutes after instilling drops before inserting lenses. · Do not discontinue abruptly; taper as directed to avoid adrenal insufficiency from systemic absorption. · Report any eye pain, vision changes, redness, or signs of infection (e.g., discharge, swelling) to your healthcare provider immediately. · This medication is for topical ophthalmic use only. Do not inject or ingest. |